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ABSTRACT
Endothelial dysfunction has been considered as one of the key initial events in the pathogenesis 
of atherosclerosis and other cardiovascular diseases (CVDs). Several studies imply that chronic 
inflammation and oxidative stress play a critical role in endothelial dysfunction. The present study 
was designed to evaluate the preventive effect of alpha-lipoic acid (ALA) on lipopolysaccharide 
(LPS) induced endothelial dysfunction in rat based on malondialdehyde (MDA) level and vascular 
cell adhesion molecules-1 (VCAM-1) expression. Thirty Wistar rats were administered ALA for 2 
weeks in different doses (30, 60, 120 mg.kg-1 BW) 1 hour before LPS 0.5 mg.kg-1 BW i.p challenge. 
The LPS was injected on 1st, 4th, and 9th day. MDA plasma level was analyzed with spectrophotometer 
λ 529 nm, and VCAM-1 expression was determined by immunohistochemistry. Pretreatment with 
ALA for 14 days could decrease plasma MDA level on LPS-induced endothelial dysfunction in rats. 
However, only one group of ALA doses, 120 mg.kg-1 BW, showed significant difference with LPS 
untreated group statistically. It was also found that ALA, in all treatment groups, could attenuate 
VCAM-1 expression. These findings suggest that ALA had a protective effect against endothelial 
dysfunction and may potentially prevent vascular inflammatory disease.
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INTRODUCTION
Cardiovascular diseases (CVDs) are a group of disorders 
or conditions affecting the heart and vascular diseases of 
the brain or blood vessels. According to the WHO facts 
sheet, 31% of all global deaths were mainly caused by 
CVDs more than any other cause. It was estimated that 
17.9 million people died from CVDs in 2016. Of these 
deaths, 85% are due to heart attack and stroke. More than 
75% of CVD deaths occur in low-income and middle-
income countries (WHO, 2014). In Indonesia, the 
proportional mortality caused by CVD reached > 35% in 
2016 (WHO, 2018).
The disorders in the cardiovascular system begin with 
endothelial dysfunction. Endothelial dysfunction is the 
early predictor of atherosclerosis (Mudau et al., 2012). 
Cardiovascular risk factors such as hypertension, 
dyslipidemia, diabetes, inflammation, obesity, and 
smoking also lead to endothelial dysfunction and 
contribute to the disease progression (Munzel et al., 
2010; Favero et al., 2014). The characteristics of that 
condition are the increasing of endothelial permeability 
and production of inflammatory mediators, such as a 
cytokine, chemokine, and adhesion molecule, especially 
Vascular Cell Adhesion Molecule-1 (VCAM-1). 
Endothelial dysfunction is followed by platelet activation, 
smooth muscle cell proliferation and migration (Favero 
et al., 2014; Liu et al., 2012; Steyers and Miller, 2014; 
Gimbrone and García-Cardeña, 2016). All of them can 
cause the development of atherogenesis, and they are 
responsible for the death caused by CVDs (Munzel et 
al., 2010, Wang & Huo, 2010).
Furthermore, oxidative stress is also responsible for 
inducing endothelial dysfunction. Oxidative stress 
means a condition in which cells are exposed to reactive 
oxygen species (ROS) in excessive level. The molecule 
acts as a messenger molecule that involves vascular 
inflammation (George & Lyon, 2010; Widlansky & 
Gutterman, 2011). Malondialdehyde (MDA) is a lipid 
peroxidation product caused by excessive ROS involved 
in the pathophysiology of endothelial dysfunction. The 
previous study showed a positive correlation between 
MDA and atherogenic index in hyperlipidemia (Yang et 
al., 2008), preeclampsia (Bharadwaj et al., 2014), and 
sickle cell nephropathy (Emokpae and Uadia, 2012).
In recent years, antioxidants become one of therapeutic 
approach to improve endothelial function in preventing 
CVDs. Alpha-lipoic acid (ALA), also known as lipoic 
acid is a dithiol compound that acts as an antioxidant. It 
is synthesized from octanoic acid enzymatically in the 
mitochondrion. It has a role in energy metabolism as a 
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cofactor for mitochondrial α-ketoacid dehydrogenases. 
It is now marketed widely and has much potential 
health benefits, especially for preventing diabetic 
polyneuropathy by improving motor nerve conduction 
of upper and lower extremities (Vijayakumar et al., 
2014). ALA provided a significant improvement in the 
manifestations of diabetic sensorimotor polyneuropathy 
(McIlduff & Rutkove, 2011). Ying et al. (2010) reported 
that in vitro, ALA was able to inhibit nuclear factor 
kappa B (NF-κB) activation, to decrease oxidative stress 
and expression of adhesion molecules in atherosclerosis 
model.
Furthermore, ALA improved cardiac function, 
attenuated VCAM-1 expression and leukocyte 
migration in myocardial through phosphoinositol-3-
Akt (PI3Akt) dependent pathway (Jiang et al., 2013). 
Unfortunately, there were only a few studies about 
ALA on lipopolysaccharide (LPS)-induced endothelial 
dysfunction in rats, especially in a constant challenge. 
Therefore, this present study was designed to evaluate 
the effectiveness of ALA on LPS-induced endothelial 
dysfunction.
METHODS
Materials
Alpha-lipoic acid (ALA) as a sample was obtained 
from Dexa Medika (Palembang, Indonesia). LPS E. 
coli 055: B55 and 2-Thiobarbituric acid (TBA) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
VCAM-1 antibody, sc-1504 was obtained from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA) and kit for 
immunohistochemistry was purchased from Biocare 
Medical (USA). Trichloroacetic acid (TCA), NaOH, HCl 
(Merck, Jakarta, Indonesia), and tetra ethoxy propane 
(TEP) (TCI, Tokyo, Japan) were used for determining the 
level of MDA plasma and other reagents, such as diethyl 
ether, propylene glycol, aqua dest, and formaldehyde 
were purchased from Bratachem (Surabaya, Indonesia).
Animals
Adult male Wistar rats (150-250 g), 2-3 months of 
age, healthy were procured from Faculty of Pharmacy, 
Airlangga University, Surabaya, Indonesia and were 
housed in suitable cages per group (n=6) at an ambient 
temperature (25±2°C), relative humidity (50± 5%), with 
a 12:12 h light-dark cycle (lights on at 07.00 am until 
7.00 pm). Animals had free access to standard pellet 
chow (Japfa Comfeed Indonesia, Surabaya, Indonesia) 
and drinking water. All animals were adapted for a 
week in the laboratory. The Animal Ethics Committee, 
Faculty of Veterinary, Airlangga University, Surabaya, 
Indonesia has approved this experimental procedure, 
with document number: 433-KE. 
Experimental Protocol
Thirty rats were randomly assigned to 5 groups. Rats in 
the healthy group received saline i.p. injection, whereas 
LPS group and all of the treatment groups were induced 
with LPS 0.5 mg.kg-1 BW in saline i.p, three times 
induction, once in every three days (1st, 4th, and 9th day). 
One hour before LPS induction, both the healthy and 
LPS groups received propylene glycol 50% 1mL/day 
per oral, whereas the treatment groups received ALA 
in different doses, 30 mg.kg-1 BW, 60 mg.kg-1 BW, and 
120 mg.kg-1 BW per oral. Both ALA or 50% propylene 
glycol was administered every day for 14 days (1st day 
to 14th day). On the 15th day, surgery was performed, and 
blood plasma was collected for determining MDA level. 
The aortic incision preparation was also obtained and 
prepared by immunohistochemistry method to measure 
the VCAM-1 expression.
Determination of plasma MDA level
A volume of 0.5 ml plasma was pipetted and put in a 10 
mL test tube, then added with 0.5 ml TCA to precipitate 
the protein. Briefly, 1 ml Sodium-TBA 1% and HCl 0,1 N 
were also added until getting 10 mL solution. They were 
mixed then heated up in a water bath at 900 C for 30 min. 
Then all the tubes were rapidly cooled and centrifuged 
at 3000 rpm for 15 min. All procedure for determining 
plasma MDA level used Thiobarbituric acid-reactive 
substances (TBARS) methods.  The absorbance of the 
pink solution was measured photometrically using 
spectrophotometer UV Vis at 529 nm. The concentration 
was expressed as µmol/L.
Immunohistochemistry and scoring of VCAM-1 
expression
Aortic tissue was fixed in 10% formaldehyde for 
a minimum of 24 hours. Then it was embedded in 
paraffin wax and was sliced at 4 µm thickness. It was 
incubated overnight in 40C with rat antibody VCAM-
1. The expression of VCAM-1, appeared dark brown 
on the surface of endothelial cells, was observed using 
Light Microscope (Olympus BX53 with camera DP21) 
and scored using the Allred system. It was calculated 
by combining the proportion of positive cells and the 
intensity of the reaction product in most of the examined 
field. The two scores are then added together to get a 
final score with eight possible values (Allred, 2005). 
Statistical analysis
The results of MDA level data were presented as 
means ± standard deviation (x̅ ± SD). Between-group 
comparisons were performed using one-way analysis 
of variance (ANOVA), followed by Tukey’s procedure 
for multiple range tests. Scoring of VCAM-1 expression 
was analyzed with Kruskal-Wallis, continued with 
Mann-Whitney test. A value of p<0.05 was considered 
significant.
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RESULTS AND DISCUSSION
Endothelial dysfunction breaks the mechanism 
of vascular homeostasis regulation. It results in 
vasoconstriction in the blood vessel wall, leading to 
leukocyte migration and adhesion. It also promotes the 
activation of platelet, thrombosis, coagulation, oxidative 
stress, and inflammation then lead to the pathogenesis of 
cardiovascular diseases (Favero et al., 2014). Endothelial 
dysfunction has been assumed as one of the critical 
initial events in the pathogenesis of atherosclerosis and 
responsible for the death caused by CVDs (Wang & 
Huo, 2010). 
Since LPS can induce inflammation in the vascular 
wall through direct activation of resident cells such as 
endothelial cells, this experimental model can be used to 
cause endothelial dysfunction. The circulating cytokines 
or other inflammatory mediators that are produced by 
LPS also develop sickness behaviour syndrome and 
oxidative stress in rat that can be protected with COX 
inhibitors (Jayashree & Prakash, 2015). LPS from E.coli 
has high toxicity. It is often considered as the most 
potent initiator for activating monokines. The structure 
of Hexa-acyl diphosphorylated lipid A with acyl chains 
of length C12–C14 is widely believed to the structure 
optimally configured to stimulate maximal activation of 
toll-like receptor-4 (TLR-4). This complex will then lead 
to monocyte activation (Erridge et al., 2002). In vivo, LPS 
E. coli (0.05 mg.mL-1 LPS in PBS or 0.5 mg.kg-1 BW i.p) 
could induce endothelial dysfunction in 24 hours through 
increasing protein expression in endothelial cells, such 
as LOX-1, NFκB, and p38- mitogen-activated protein 
kinase (MAPK) (Zhao et al., 2014). The LPS-mediated 
inflammatory environment also affects iNOS, TNFα and 
IL-6 mRNA levels in a concentration-dependent manner 
(Baek et al., 2018). Since it was known that LD50 of E. 
coli LPS i.p in the rat is 5 mg.kg-1 BW, and minimum 
dose 1 mg.kg-1 BW still caused some deaths in 24 hours 
(Ashour et al., 2011), thus in this present study LPS dose 
0.5 mg.kg-1 BW was used. Three times inductions, once 
in every three days, are being considered to obtain the 
persistent effect of endothelial dysfunction. 
Effect of ALA on plasma MDA level 
A growing body of evidence suggests that increased 
production of ROS can induce endothelial dysfunction 
(Munzel et al., 2010). LPS-induced rabbits showed 
increased production of protein oxidation (carbonyl) and 
lipid peroxidation (MDA & 4-hydroxy alkene) both in 
tissue or plasma (Gonzalo et al., 2010). The mechanism 
explained that a complex of LPS/TLR-4 would trigger 
intracellular ROS production mediated by NADPH 
oxidase and through activation NFκB and MAPK 
pathway will induce the increasing of pro-inflammatory 
mediators. The increasing of MDA level will reduce 
endothelial function (Lee et al., 2012). 
The result of this study showed that three times inductions 
of LPS 0.5 mg.kg-1 BW i.p, once in every three days 
induced oxidative stress as shown by significant increase 
of MDA level (p<0,001), almost two folds compared 
to the healthy group. Treatment with ALA at a dose 
30 mg.kg-1 BW, 60 mg.kg-1 BW, and 120 mg.kg-1 BW 
for 14 days administered 1 hour before LPS challenge 
decreased plasma MDA level that was dose-dependent. 
Figure 1 - Effects of ALA on plasma MDA mean concentration in rats
LPS 0.5mg.kg-1 BW i.p. was induced three times, once every three days (in 1st, 4th, 
and 7th day). ALA at dose 30; 60; 120 mg.kg-1 BW) was administered by oral gavage, 
every day for 14 days, 1 hour before LPS challenge. Plasma MDA level was measured 
by the TBARS method using spectrophotometer UV-Vis    529 nm. MDA concentration 
was shown as mean     SD (n=5). *p<0.001 vs healthy group; #p<0.001 vs LPS group 
(Tukey’s multiple comparison tests).
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There was a significant difference observed at p<0.001 
(Figure 1). Tukey’s tests were then performed, showing 
only ALA 120 mg.kg-1 BB was statistically significant 
compared to LPS untreated group (p<0.001), but it was 
not significant compared to the healthy group (p=0.677).
The decreasing plasma MDA level, especially after 14 
days of treatment with ALA would decrease oxidative 
stress.  As a biological antioxidant, ALA has two 
mechanisms, direct and indirect activities. As a direct 
antioxidant, ALA and its reduction form, dihydrolipoic 
acid (DHLA) scavenge hydroxyl radicals, singlet 
oxygen, and hypochlorous acid. They also regenerate 
endogenous antioxidants such as vitamins C and E, and 
GSH by reducing the oxidized forms. Whereas as an 
indirect antioxidant, both ALA & DHLA have metal-
chelating properties due to dithiolane ring’s activities. 
In vitro, lipoic acid can chelate of divalent metal ions 
and form stable complexes with Zn2+, Cu2+, Mn2+, and 
Fe2+ (Goraca et al., 2011, Rochette et al., 2015). The 
other study showed that preincubation of the HUVECs 
with ALA increased cell viability, all oxLDL effect, and 
decreased MDA content (Liu, 2011). In vivo, in LPS-
induced model, ALA decreased tissue MDA level & 
H2O2 in lymph, brain, heart (Goraca et al., 2011; Goraca 
et al., 2013). In the sepsis model, ALA balanced redox by 
decreasing testis MDA, NO, 8-hydroxydeoxyguanosine 
(8-OHdG) level (Ashour et al., 2011). It could also 
improve endothelial function due to reducing MDA 
level both in plasma and aortic tissue in a diabetic model 
(Ying et al., 2010), ischemic myocardial (Wang et al., 
2011) and hypercholesterolemia rat (Sari et al., 2016). 
Effect of ALA on VCAM-1 expression 
Adhesion molecules were also essential markers of 
endothelial dysfunction. Several mediators, including 
microbial stimulation of TLRs, production of cytokines, 
excessive levels of ROS, or turbulent blood flow at vessel 
bifurcations induce the expression of VCAM-1 (Milis et 
al., 2011). The up-regulation of VCAM-1 is a critical 
step in leukocyte or monocyte migration to intima during 
inflammation (Wu et al., 2012). Lipopolysaccharide-
induced VCAM-1 expression (Jiang et al., 2013) and 
leukocyte adhesion in lung tissue (Wu et al., 2012). In 
vitro, LPS also promoted VCAM-1 expression and other 
adhesion molecules in human umbilical cord vein cell 
(HUVEC) (Liu et al., 2012; Wu et al., 2012, Baek et 
al., 2018), mesangial cell (Lee et al., 2012); vascular 
smooth muscle cell (Meng et al., 2013); mouse glial 
and neuronal cultures (Leow-Dyke et al., 2012). The 
mechanism involves TLR-4 stimulation, then trigger 
Figure 2 - Effects of ALA on VCAM-1 expression on the surface of 
vascular walls (endothelial cells) of rat aortic tissue (see arrow sign,          ). 
LPS 0.5mg.kg-1 BW i.p. was induced three times, once every three days (in 1st, 4th, and 
7th day). ALA at dose 30; 60; 120 mg.kg-1 BW was given by oral gavage, every day for 
14 days, 1 hour before LPS challenge. VCAM-1 expression was observed by staining 
aortic tissue with the VCAM-1 polyclonal antibody (1:100), magnification 400x. (A) 
Healthy group, (B) LPS 0.5 mg.kg-1 BW, untreated group, (C) LPS+ALA 30 mg.kg-1 
BW, (D) LPS+ALA 60 mg.kg-1 BW, dan (E) LPS+ALA 120 mg.kg-1 BW. 
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ROS intracellular production and MAPK & NFκB 
pathway activation (Liu et al., 2012; Lee et al., 2012; 
Wu et al., 2012; Burger & Touyz, 2012). Finally, they 
induce LOX-1 expression via TLR4/MyD88/ROS, then 
activated the p38MAPK-NF-κB pathway to promotes 
ox-LDL endocytosis and acts as an adhesion molecular 
supporting endothelial-monocyte interaction (Zhao et 
al., 2014). 
By understanding the molecular mechanism of vascular 
inflammation in atherosclerosis are now yielding novel 
target for pharmacotherapy (Rahmathulla & Devi, 
2015). Since ROS could induce VCAM-1 production 
and expression, antioxidants were believed as a potential 
agent in endothelial dysfunction by blocking its signal 
transduction, and VCAM-1-dependent inflammation. 
The signalling of VCAM-1 became a target for 
intervention by antioxidants or by pharmacological 
agents during inflammatory diseases (Mills et al., 2011), 
especially in cardiovascular disease.
The VCAM-1 expression on the surface of endothelial 
cells was determined by staining aortic tissue with rat 
antibody VCAM-1 (Figure 2). In a healthy group, 
negative staining of aortic tissue was observed (Figure 
2A). Positive staining was demonstrated by dark brown 
(noted by black arrow) on the surface of endothelial 
cells from all groups threat with LPS 0.5 mg.kg-1 BW. 
The most robust expression was shown in the untreated 
group (Figure 2B). The protein expression on the 
endothelial cell surface was attenuated after 14 days ALA 
administration in LPS challenge rats, depending on the 
dose, as illustrated in Figure 2C (ALA 30 mg.kg-1 BW), 
Figure 2D (ALA 60 mg.kg-1 BW), and Figure 2E (ALA 
120 mg.kg-1 BW). The scoring of VCAM-1 expression, 
which determined by the Allred system, interpreted the 
weak staining in all ALA treatment groups (data was 
not shown). Then, analysis with Kruskal-Wallis showed 
that ALA administration in the treatment group (30, 60, 
and 120 mg.kg-1 BW) significantly attenuated VCAM-1 
expression (p<0.001).
This present study showed that ALA administration, as 
one of the potential antioxidant could attenuate VCAM-
1 expression. In line with this result, in vitro assays using 
HUVEC (Tomo et al., 2015) and homocysteine-induced 
injuries to human aortic endothelial cells (HAECs) (Hu 
et al., 2016). Whereas in vivo, ALA treatment markedly 
and dose-dependently attenuated the expression of 
VCAM-1 in ovariectomized Ldlr-/- mice (Shen et al., 
2018). Lipoic acid decreased oxidative stress,  inhibited 
NF-κB activation, improved vascular reactivity, 
attenuated expression of adhesion molecules, especially 
mRNA expression of VCAM-1 in thoracic aorta of 
Watanabe heritable hyperlipidemic (WHHL) and also 
reduce atherosclerotic plaques in the abdominal aorta in 
rabbits (Ying et al., 2010) and atherosclerotic mice (Lee 
et al., 2012).
The arrangement of ALA in attenuating VCAM-1 
expression involves the activation of the PI3K/Akt 
pathway that can negatively regulate the NFκB activation 
pathway.  Previous studies showed that ALA ameliorated 
inflammation and apoptosis in aortic tissues of aged type 
II diabetes rat (Bitar et al., 2010) and attenuated LPS-
induced cardiac dysfunction (Jiang et al., 2013) through 
a PI3K/Akt-dependent mechanism. The PI3K/Akt 
pathway can negatively regulate the NFκB activation 
pathway. Lipoic acid also inhibited IκBα degradation 
and NFκB activation through inhibition of IKK2 rather 
than its antioxidant function (Ying et al., 2011). In 
contrast, lipoic acid as an antioxidant may also oxidize 
sulfhydryl groups or form mixed disulfides on proteins, 
thus influencing the changes in the thiol redox status of 
NF-κB as a redox-sensitive transcription factor (Goraca 
et al., 2011). The suppression of NF-κB will lead to a 
decrease in the production of pro-inflammatory genes, 
especially VCAM-1. Thus, the inflammation responses 
were also limited as the decreasing of the VCAM-1 
output.
CONCLUSION
 
In conclusion, ALA may have a protective effect against 
LPS-induced endothelial dysfunction in rats and have 
a potential health benefit in preventing inflammatory 
vascular disease. However, further studies in detail 
are required to explore other mechanisms of ALA in 
preventing endothelial dysfunction. 
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